These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25931335)

  • 41. Clinical significance of N-terminal Pro-B-type natriuretic peptide (NT-proBNP) in hemodialysis patients.
    Helal I; Belhadj R; Mohseni A; Bazdeh L; Drissa H; Elyounsi F; Abdallah TB; Abdelmoula J; Kheder A
    Saudi J Kidney Dis Transpl; 2010 Mar; 21(2):262-8. PubMed ID: 20228511
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Associations of N-terminal pro-B-type natriuretic peptide with kidney function decline in persons without clinical heart failure in the Heart and Soul Study.
    Park M; Vittinghoff E; Shlipak MG; Mishra R; Whooley M; Bansal N
    Am Heart J; 2014 Dec; 168(6):931-9.e2. PubMed ID: 25458658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Socioeconomic position is associated with N-terminal pro-brain natriuretic peptide (NT-proBNP)-Results of the population-based Heinz Nixdorf Recall study.
    Rudman M; Frank M; Emmel C; Matusch E; Kara K; Mahabadi AA; Erbel R; Jöckel KH; Dragano N; Schmidt B
    PLoS One; 2021; 16(8):e0255786. PubMed ID: 34415953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Decreasing ratio of plasma N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide according to age.
    Koch AM; Rauh M; Zink S; Singer H
    Acta Paediatr; 2006 Jul; 95(7):805-9. PubMed ID: 16801175
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population.
    Zhu Q; Xiao W; Bai Y; Ye P; Luo L; Gao P; Wu H; Bai J
    Clin Interv Aging; 2016; 11():245-53. PubMed ID: 27013868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients.
    Guo Q; Bárány P; Qureshi AR; Snaedal S; Heimburger O; Stenvinkel P; Lindholm B; Axelsson J
    Am J Nephrol; 2009; 29(6):516-23. PubMed ID: 19077418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.
    Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Pedretti RF; Lagioia R; Frigerio M; Catanzaro R; Oliva F
    Int J Cardiol; 2013 Oct; 168(3):2120-6. PubMed ID: 23395457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PATHFAST NT-proBNP (N-terminal-pro B type natriuretic peptide): a multicenter evaluation of a new point-of-care assay.
    Zaninotto M; Mion MM; Di Serio F; Caputo M; Ottomano C; Plebani M
    Clin Chem Lab Med; 2010 Jul; 48(7):1029-34. PubMed ID: 20406130
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
    Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
    Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased plasma N-terminal pro-B-type natriuretic peptide and markers of inflammation related to atherosclerosis in patients with primary hyperparathyroidism.
    Ogard CG; Engelmann MD; Kistorp C; Nielsen SL; Vestergaard H
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):493-8. PubMed ID: 16268799
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction.
    Costello-Boerrigter LC; Boerrigter G; Redfield MM; Rodeheffer RJ; Urban LH; Mahoney DW; Jacobsen SJ; Heublein DM; Burnett JC
    J Am Coll Cardiol; 2006 Jan; 47(2):345-53. PubMed ID: 16412859
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of menopause age and N-terminal pro brain natriuretic peptide: the Multi-Ethnic Study of Atherosclerosis.
    Ebong IA; Watson KE; Goff DC; Bluemke DA; Srikanthan P; Horwich T; Bertoni AG
    Menopause; 2015 May; 22(5):527-33. PubMed ID: 25290536
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma N terminal pro-brain natriuretic peptide levels and its determinants in a multi-ethnic population.
    Abdulle AM; Nagelkerke NJ; Adem A; Abouchacra S; Pathan JY; Al-Rukhaimi M; Suleiman MN; Mathew MC; Nicholls MG; Obineche EN
    J Hum Hypertens; 2007 Aug; 21(8):647-53. PubMed ID: 17460711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimated glomerular filtration rate is associated with both arterial stiffness and N-terminal pro-brain natriuretic peptide in newly diagnosed hypertensive patients.
    Gür M; Uçar H; Kuloğlu O; Kıvrak A; Şeker T; Türkoğlu C; Özaltun B; Kaypaklı O; Şahin DY; Elbasan Z; Tanboğa Hİ; Çaylı M
    Clin Exp Hypertens; 2014; 36(6):374-9. PubMed ID: 24432984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The influence of diabetes on the relationship between N-terminal pro-B-type natriuretic peptide and body mass index.
    Kim BH; Kim IJ; Cho KI; Kim SM; Lee HG; Kim TI
    J Int Med Res; 2010; 38(5):1737-48. PubMed ID: 21309488
    [TBL] [Abstract][Full Text] [Related]  

  • 57. N-terminal pro-B-type natriuretic peptide is inversely associated with metabolic syndrome in hypertensive patients.
    Chang HR; Hsieh JC; Hsu BG; Wang LY; Yu-Chih Chen M; Wang JH
    Am J Med Sci; 2014 Sep; 348(3):210-4. PubMed ID: 24736765
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical implications of B-type natriuretic peptide and N-terminal pro--B-type natriuretic peptide in the care of the vascular surgery patient.
    Wayne Causey M; Singh N
    Semin Vasc Surg; 2014 Dec; 27(3-4):143-7. PubMed ID: 26073822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
    Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
    Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation.
    Roldán V; Vílchez JA; Manzano-Fernández S; Jover E; Gálvez J; Puche CM; Valdés M; Vicente V; Lip GY; Marín F
    Stroke; 2014 Mar; 45(3):696-701. PubMed ID: 24519407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.